Warren Denning

Medical Science Liaison at Juno Therapeutics Inc

Warren Denning's Professional Contact Details

Email (Verified)

****@junotherapeutics.com

Get Email Address

(206) 582-1600

Location

Houston, Texas, US

Company

Juno Therapeutics Inc

Person Seniority

entry

Warren Denning's Current Company Details

Juno Therapeutics Inc

Seattle, Washington, US • 598 Employees

biotechnology

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children's Research Hospital patented technology for CD19 directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children's Research Hospital.

Founded Year

2013

Organization Website

junotherapeutics.com

Organization Revenue

79400

Current Technologies

outlook

gmail

google apps

omniture adobe

mobile friendly